
|Videos|April 26, 2023
Treatment Sequencing in Advanced RCC: Updates from 2023 ASCO GU
Author(s)Bradley McGregor, MD
Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5





































